Yes, there is a pill version of Wegovy — here is what UK patients need to know

Step 1, Understanding what the Wegovy pill actually is

The Wegovy tablet is oral semaglutide, produced by Novo Nordisk and approved by the MHRA on 11 June 2026. It works through the same mechanism as the injection: semaglutide activates GLP-1 receptors involved in appetite regulation and slows gastric emptying, helping you feel full sooner and stay full for longer. What changes is the delivery. The tablet uses a co-formulation with SNAC, an absorption enhancer that allows semaglutide to cross the stomach lining and reach the bloodstream when taken correctly.

The distinction between the Wegovy tablet and Rybelsus matters here. Rybelsus is also oral semaglutide, but it is licensed only for type 2 diabetes, not weight loss, and it comes in 3mg, 7mg and 14mg strengths. The Wegovy weight-loss tablet schedule is entirely separate: 1.5mg, 4mg, 9mg and 25mg. Those are not interchangeable with Rybelsus doses. If you have been wondering whether there is a Wegovy pill, the tablet approved by the MHRA in June 2026 is the answer to that question, and it is what is now licensed for weight loss in the UK. If you have come across references to an oral semaglutide pill for weight loss, the Wegovy tablet is what is now licensed for that purpose in the UK.

It is licensed for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity. A prescriber decides whether you meet those criteria, and whether the tablet specifically suits your situation.

Step 2, How you take it and what the titration looks like

Taking the Wegovy tablet correctly matters more than with most medicines. It must be swallowed whole, first thing in the morning, on a completely empty stomach, with no more than a small sip of plain water, roughly 120ml. Then you wait at least 30 minutes before eating, drinking anything else (including coffee or tea), or taking other oral medicines. If you eat or drink too soon, far less semaglutide is absorbed and the dose is effectively wasted.

One practical way to think about it: the tablet goes down before the kettle goes on. That small habit makes the timing concrete and easy to repeat.

The titration schedule starts at 1.5mg and moves through 4mg, then 9mg, before reaching the 25mg maintenance dose, with a minimum of one month at each level. The gradual increase is there to let your digestive system adjust. Patients already established on the 2.4mg weekly injection may be able to move directly to the 25mg tablet, but that switch is always a clinical decision. If you want to understand how the pill version of Wegovy compares with the injectable, including how the two formats differ in practice, that page goes into more detail alongside the Wegovy pill overview.

Step 3, What the trial evidence shows

The MHRA approval was supported by results from the OASIS 4 phase 3 trial, which followed 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes, over 64 weeks. Participants took the oral semaglutide alongside lifestyle changes. Average weight loss across the treatment group was around 13.6%, compared with around 2.4% in the placebo group. Among those who stayed fully adherent to treatment throughout, the figure reached approximately 16.6%. That second number is worth framing carefully: it reflects the best-case picture for people who followed the protocol precisely, not the typical outcome for the whole group.

The most common side effects in the trial were gastrointestinal (nausea, diarrhoea, vomiting) affecting around 74% of participants on the tablet compared with 42% on placebo. These were generally mild to moderate and tended to settle as the body adjusted, particularly during the early weeks of titration. You can read the semaglutide tablets guide for a more detailed look at what to expect by dose stage. The MHRA's medicines information for semaglutide covers the full side-effect profile and is worth reading alongside any prescriber conversation.

Step 4, Access, cost and what private treatment involves

At the time of writing (summer 2026), the Wegovy tablet is not available on the NHS. A NICE technology appraisal would be required before it could be commissioned, and that process typically takes time after a new approval. For now, access is through private prescription only.

That means the cost falls on the patient, and it is reasonable to want to understand what that involves before proceeding. A legitimate private prescription for any weight-loss medicine should always include a clinical assessment, not just a checkout. For context on how private semaglutide tablet pricing compares across the market, that page covers what is typically included and what to check before committing.

At nume, every consultation is reviewed personally by a GPhC-registered Independent Prescriber, not by an automated system. Treatment is dispatched the same day, once approved, and delivered free by DPD the next working day in plain packaging. There are no subscriptions and no auto-renewals; every repeat order gets its own clinical review. If you want to explore whether the Wegovy tablet or another licensed treatment might suit you, our weight-loss treatment overview sets out the options clearly.